10-Q: Stemtech Corporation Reports Increased Net Loss Amid Revenue Decline, Cites Strategic Investments and Cost Controls

Stemtech Corporation reported a higher net loss for Q1 2025 compared to the prior year, driven by decreased net sales despite significant reductions in operating and interest expenses, while facing substantial doubt about its ability to continue as a going concern.

Summary

• Net sales for the three months ended March 31, 2025, decreased to $868,046 from $1,382,570 in the same period of 2024, reflecting a strategic shift away from short-term volume growth.
• Cost of goods sold decreased to $147,782 in Q1 2025 from $345,369 in Q1 2024, indicating improved efficiency and cost management.
• Total operating expenses favorably decreased to $1,925,169 in Q1 2025 from $2,048,012 in Q1 2024, primarily due to reductions in commissions and selling/marketing expenses.
• Total non-operating expenses decreased to $253,821 in Q1 2025 from $409,818 in Q1 2024, mainly due to a significant reduction in interest expense.
• Net loss for the quarter ended March 31, 2025, was $(1,458,726), a slight increase from $(1,420,629) in Q1 2024, attributed by management to strategic investments for future growth.
• The company reported an accumulated deficit of approximately $32.1 million and a working capital deficiency of approximately $8.6 million as of March 31, 2025.
• Net cash used in operating activities improved to $(710,507) in Q1 2025 from $(1,017,485) in Q1 2024.
• Cash balance increased to $305,836 as of March 31, 2025, from $255,298 at December 31, 2024.
• The company continues to operate with recurring net losses and negative cash flows from operations since inception, raising substantial doubt about its ability to continue as a going concern.
• The company has no operating lease commitments as of March 31, 2025, following the expiration of its office lease on September 30, 2024.

Sentiment

Score: 2

Explanation: The company faces significant financial challenges, including recurring losses, a substantial accumulated deficit, and a going concern warning. While there are positive signs in cost management and debt reduction, the sharp decline in revenue and increasing net loss indicate a deteriorating financial position. The need for future capital raises and potential dilution further contribute to a negative outlook.

Positives

• Cost of goods sold decreased by $181,804, reflecting efficiency improvements and effective cost management strategies despite reduced sales.
• Total operating expenses decreased by $122,843 due to effective cost management initiatives, including strategic reductions in commissions and selling and marketing expenses.
• Interest expense significantly decreased to $245,368 in Q1 2025 from $430,959 in Q1 2024, indicating enhanced debt management strategies.
• Net cash used in operating activities decreased from $1,017,485 in Q1 2024 to $710,507 in Q1 2025, showing improved operational cash burn.
• Cash balance increased to $305,836 as of March 31, 2025, from $255,298 at December 31, 2024.
• The company has streamlined operations by outsourcing U.S. order fulfillment and transitioning U.S. customer service to Mexico offices, leading to cost savings and improved synergistic benefits.
• Reduced insurance coverage costs due to the new inventory process.

Negatives

• Net sales decreased significantly by 37.2% to $868,046 in Q1 2025 from $1,382,570 in Q1 2024.
• Gross profit decreased to $720,264 in Q1 2025 from $1,037,201 in Q1 2024.
• Operating loss increased to $(1,204,905) in Q1 2025 from $(1,010,811) in Q1 2024.
• Net loss increased to $(1,458,726) in Q1 2025 from $(1,420,629) in Q1 2024.
• The company has experienced recurring net losses and negative cash flows from operations since inception.
• An accumulated deficit of approximately $32.1 million as of March 31, 2025.
• A working capital deficiency of approximately $8.6 million at March 31, 2025.
• The company's ability to continue as a going concern is in substantial doubt.
• The company previously experienced out-of-stock situations, which could hinder growth without additional capital.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring net losses and negative cash flows from operations, and a significant accumulated deficit and working capital deficiency.
• The company will continue to require substantial funds to implement its new investment acquisition plans and meet operating cash flow requirements.
• Future financing activities, such as private placements of common stock, preferred stock offerings, and issuances of debt and convertible debt instruments, may not be available on acceptable terms or at all.
• Additional issuances of equity or convertible debt securities will result in dilution to current shareholders, and such securities might have rights, preferences, or privileges senior to common stock.
• The company may incur substantial costs in pursuing future capital and financing, including investment banking, legal, and accounting fees.
• Non-cash expenses in connection with certain securities, such as convertible notes and warrants, could adversely impact financial condition.
• The ability to obtain needed financing may be impaired by factors in the capital markets, both generally and specifically in the nutraceutical industry.
• There is a risk of ceasing operations if adequate funds are not available or if the company is unable to execute its business plan, increase revenue, and reduce expenditures.
• The company is involved in ongoing litigation with a former CEO regarding alleged unpaid salary and vacation pay totaling approximately $267,000, which could result in an adverse financial outcome.

Future Outlook

The company expects to require additional capital to meet its long-term operating requirements and plans to raise funds through the sale of equity or debt securities. Management conservatively believes that with current cash on hand and working expenditures, sales can be reinvigorated to be consistent with historical revenue levels. The company projects adding 30,000 new independent business partner representatives over the next 12 to 24 months and has engaged marketing and social media professionals to initiate new strategies. The overall stem cell global market, including stem cell therapy and pharma, is projected to reach $30 billion by 2030, positioning Stemtech for growth as awareness increases.

Management Comments

• "The current quarter reflects the Company's ongoing shift toward streamlining operations and focusing on long-term distributor quality and sustainability rather than short-term volume growth."
• "This period of recalibration has allowed us to focus resources on core, high-performing markets and reduce dependency on lower-margin geographies and begin implementing improvements in customer engagement and retention tools, which are expected to yield benefits in upcoming quarters."
• "The improvement in cost of goods sold was driven by the Company's focus on efficiency improvements and cost management strategies, despite the reduction in sales."
• "The reduction in total operating expenses was largely attributed to our effective cost management initiatives, which included strategic reductions in commissions and selling and marketing expenses."
• "The improvement in non-operating expenses was primarily driven by a significant reduction in interest expense, which reflects the Company's enhanced debt management strategies and ongoing efforts to optimize its capital structure and reduce financing costs."
• "The slight year-over-year increase in net loss was primarily due to higher operating expenses associated with strategic investments aimed at positioning the Company for future growth."
• "These investments are expected to drive long-term value as the Company focuses on enhancing its operational infrastructure and expanding its market presence."
• "Management conservatively believes that given the cash on hand and working expenditures as describe above, we can reinvigorate sales to be more consistent with the company's previous revenue historically, as we were recognized 4 times in the Inc 5000 Magazines list of fastest growing companies."
• "As the pioneer in stem cell nutrition, Stemtech is well positioned for growth as awareness increases."

Industry Context

Stemtech operates in the nutraceutical and stem cell nutrition market, which is part of the broader stem cell global market projected to reach $30 billion by 2030. The company positions itself as a pioneer in stem cell nutrition, aiming to capitalize on increasing awareness of stem cell benefits. Its direct-to-consumer (DTC) network marketing model is presented as uniquely positioned in the post-pandemic economy, adapting to supply chain issues by not requiring upfront inventory buy-in and offering monthly shipments for recurring sales. This model places the company at the intersection of the e-commerce, social, and gig economies.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results for direct assessment against industry standards.
• Stemtech's recurring net losses, negative cash flows from operations, and significant accumulated deficit and working capital deficiency indicate a financial performance that falls significantly below typical industry standards for healthy, growing companies.
• While the company highlights its pioneering role in stem cell nutrition and the projected growth of the broader stem cell market, its current financial metrics suggest it is not yet effectively capitalizing on this market potential compared to established, profitable players in the health and wellness or direct selling industries.

Corporate Governance

Legal Proceedings

• An ongoing lawsuit filed on August 6, 2019, by a former CEO against Stemtech HealthSciences Corp., alleging unpaid salary and vacation pay totaling approximately $267,000. The company has accrued $267,000 related to this matter and considers the claims without merit, having filed a counterclaim. The former CEO's request for summary judgment was dismissed on March 3, 2023, but the litigation continues.

Related Party Transactions

• John W. Meyer, President and COO, provided a loan of $105,000 to the company during 2024.
• On March 19, 2024, the company issued 900,000 shares of common stock to the Chief Financial Officer as stock-based compensation, valued at $45,000.
• On March 19, 2024, the company issued an aggregate of 5,000,000 shares of common stock to five directors (1,000,000 each) as stock compensation, valued at $150,000.
• The company recognized $440,256 in stock compensation expense during 2024 related to awards previously granted to its Chairman and CEO.
• On February 20, 2025, John W. Meyer, President & COO, made a loan of $25,000 to the company.
• On March 6, 2025, the company issued 5,000,000 shares to five directors, valued at $150,000.
• The company amortized $108,260 of previous stock compensation granted to its Chairman and CEO during Q1 2025.
• As of March 31, 2025, the company owed outstanding principal balance of convertible promissory notes of $134,798 to Mr. John W. Meyer and $25,000 to Mr. Darryl V. Green.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from potential future equity raises and existing convertible debt. The going concern warning and recurring losses pose a substantial risk to investment value. Stock-based compensation to management and directors also contributes to dilution.
• **Employees:** The company has reduced its labor force and outsourced functions, which could impact job security for some, but also aims to enhance operational efficiency.
• **Customers:** The company's focus on 'long-term distributor quality and sustainability' and 'improvements in customer engagement and retention tools' suggests a potential for improved customer experience, but past out-of-stock situations could have negatively impacted customer satisfaction.
• **Suppliers:** The company's working capital deficiency and reliance on factoring arrangements could indicate potential payment delays or strained relationships with suppliers, though cost management efforts might mitigate some pressure.
• **Creditors:** The company's significant notes payable and convertible debentures, coupled with its going concern status, indicate elevated credit risk. The reduction in interest expense is positive, but the overall debt burden remains high.

Next Steps

• Execute business plan to increase revenue and reduce expenditures to address going concern issues.
• Implement improvements in customer engagement and retention tools, expected to yield benefits in upcoming quarters.
• Continue efforts to optimize manufacturing processes and manage raw material costs effectively.
• Attract and add 30,000 new independent business partner representatives over the next 12 to 24 months.
• Continue to engage experienced marketing and social media professionals to initiate new marketing strategies.
• Seek additional capital through private placements of common stock, preferred stock offerings, and issuances of debt and convertible debt instruments.
• Continue to defend against the ongoing legal proceeding with the former CEO.

Key Dates

Recommendation

Keywords

Stemtech Corporation, 10-Q, Quarterly Report, Financial Results, Net Loss, Revenue Decline, Operating Expenses, Cost Management, Going Concern, Working Capital Deficiency, Accumulated Deficit, Nutraceuticals, Stem Cell Nutrition, Direct Selling, Network Marketing, SEC Filing, Debt Management, Capital Raise, Litigation, Related Party Transactions